Latest Commercialization News

Elanor Investors Group updates on its ongoing asset divestment program, debt covenant negotiations, and corporate governance reforms as it navigates balance sheet challenges and strategic options.

Codeifai Limited (ASX – CDE) has agreed to acquire Antenna Transfer, an AI-driven quantum-secure platform, marking a strategic expansion into next-generation digital security. The deal positions Codeifai at the forefront of quantum-resilient infrastructure for high-security industries.

Emperor Energy secures independent validation of its Judith Gas Field resources, boosting unrisked prospective volumes to 1.86 trillion cubic feet and setting sights on a mid-2026 appraisal well to advance development.

Echo IQ has initiated a pivotal clinical validation study with the Mayo Clinic Platform to test its EchoSolv HF software, marking the final step before its planned FDA submission in late 2025.

Mesoblast has secured FDA agreement on key requirements for its Biologics License Application for Revascor, targeting ischemic heart failure patients with reduced ejection fraction. The company aims for accelerated approval by year-end 2025.

Medallion Metals has taken a crucial step by acquiring 258 hectares near Ravensthorpe to meet environmental offset requirements, advancing its gold project approvals under federal law.

Kinetiko Energy has signed a non-binding term sheet with FFS Refiners to co-develop a pilot LNG plant at Brakfontein, aiming to fast-track gas production and supply to South Africa's industrial market.

Tasman Resources has identified a large, prospective conductive target zone near its historic Vulcan drill hole VUD 008, opening a promising new chapter in copper-gold exploration.

MRG Metals has achieved a pivotal milestone with the granting of the Corridor South 11137 Mining Licence in Mozambique, setting the stage for production within 12 to 18 months under its fully funded Corridor Sands Project.

Critica Limited has appointed Jacob Deysel as CEO to accelerate development of its Jupiter Rare Earth Project, signalling a strategic shift from exploration to production readiness. Deysel’s extensive global mining experience and rare earths expertise position the company for its next growth phase.

Prescient Therapeutics has launched a $7 million Share Purchase Plan at a notable discount to fund the next phase of clinical trials for its promising PTX-100 cancer therapy. The capital raise aims to accelerate progress toward regulatory approval and patient access.

Artrya Limited announces a strategic leadership reshuffle with co-founder John Konstantopoulos stepping into the CEO role as the company prepares for its U.S. commercial launch of the Salix® AI-powered platform.